Close Menu


The company said the improvements it has made to its business during the pandemic will translate to significant increases in growth once it ends.

The company said clinical services revenues rose 66 percent during the quarter, driven by significant year-over-year growth in the volume of accessions.

The company said its clinical lab revenues rose nearly 5 percent, but revenues from its life sciences business fell 26 percent because of the COVID-19 pandemic.

The program is intended to help make testing for the virus more accessible to New Yorkers, the partners said.

The Enzo and Access Bio tests may be performed by any CLIA-certified high complexity lab, while use of Gene By Gene's test is limited to its developer.

The company said clinical services revenues and diagnostic testing volumes fell during the quarter due to the negative impact of the COVID-19 pandemic.

LabCorp's test is being made available pursuant to FDA guidance that allows high-complexity, CLIA-certified labs to perform their own tests for SARS-CoV-2.

The company said clinical services revenues and diagnostic testing volumes rose during the quarter, but that PAMA continued to negatively affect reimbursements.

The GenFlex is a sample-to-result molecular diagnostic platform that includes sample collection, processing, amplification, and detection, the company said.

The firm also said it is contemplating selling its therapeutics division, and appointed David Bench as its new CFO.


Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.